These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 11 2025
0mins
Should l Buy NVO?
Source: NASDAQ.COM
Market Overview: The S&P 500 has declined 4.5% this year, losing all post-election gains, while international markets, particularly through Vanguard ETFs, have shown better performance with significant returns, suggesting a potential shift in investment focus.
Investment Recommendations: Analysts recommend considering international dividend stocks for reliable passive income amidst market volatility, highlighting the Vanguard International Dividend Appreciation ETF and the Vanguard International High Dividend Yield ETF as strong options for investors looking to capitalize on global growth opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 54.67 USD with a low forecast of 42.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 47.640
Low
42.00
Averages
54.67
High
70.00
Current: 47.640
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Expects Earnings Decline in 2026
- Earnings Guidance Decline: Novo Nordisk's 2025 earnings report revealed a grim outlook for 2026, with sales and earnings expected to decline between 5% and 13%, primarily due to lower GLP-1 drug prices in the U.S., indicating significant market pressures and uncertainty regarding future profitability.
- Surge in GLP-1 Demand: Despite these challenges, the company's new GLP-1 pill attracted 170,000 patients within just four weeks of launch, far exceeding management's expectations, highlighting the potential growth opportunities in the weight-loss drug market.
- Increased Market Acceptance: The preference for oral medications over injections among consumers suggests that Novo Nordisk's GLP-1 pill could tap into a larger market, and the pricing agreement with the U.S. government further boosts demand, creating a favorable environment for sales growth.
- Optimistic Long-Term Outlook: Although Novo Nordisk's stock has lost two-thirds of its value since its peak in 2024, the early success of the pill indicates that future volume could offset the pricing pressures expected in 2026, with the CEO's comments reflecting a positive internal outlook for the company's future.
See More
Novo Nordisk Shares Surge After Competitor Withdraws Drug
- Stock Surge: Novo Nordisk shares jumped 8% on Monday following Hims & Hers' announcement to withdraw its copycat weight-loss pill, indicating increased market confidence in Novo Nordisk's products.
- Legal Threats: Novo Nordisk and the FDA had threatened legal action against Hims & Hers, prompting the withdrawal, which not only protects Novo Nordisk's market share but may also reshape competitive dynamics in the industry.
- Market Reaction: Hims & Hers stated on social media that after constructive conversations with industry stakeholders, they decided to stop offering the treatment, a move that could further solidify Novo Nordisk's leadership in the weight-loss drug market.
- Commitment to Safe Care: Hims & Hers emphasized its commitment to providing safe, affordable, and personalized care, and while the withdrawal may impact its trust among consumers, it reflects a strategic pivot in response to regulatory pressures.
See More
Eli Lilly Stock Bounces Back 2.4% After FDA Action Against Hims & Hers
- Stock Recovery: Eli Lilly (LLY) shares rebounded 2.4% by 9:50 a.m. ET on Monday, reflecting a recovery in market confidence after last week's decline due to Hims & Hers' announcement of an Ozempic lookalike, indicating resilience in its core product offerings.
- FDA Regulatory Action: The FDA's plans to crack down on Hims & Hers, potentially limiting access to ingredients for manufacturing Ozempic copies, triggered a positive market response over the weekend, further boosting Eli Lilly's stock price.
- Reduced Competitive Threat: Hims & Hers' decision to halt the sale of its Ozempic copycat alleviates competitive pressure on Eli Lilly, particularly regarding its pricing strategy for Zepbound and Mounjaro, thereby reinforcing Lilly's market position.
- Legal Action Impact: Novo Nordisk's lawsuit against Hims & Hers, seeking to prevent the sale of copycat drugs, not only protects Novo's market share but also indirectly benefits Eli Lilly by enhancing the competitive edge of its higher-priced products in the market.
See More
Hims & Hers Faces Serious Regulatory Consequences
- Increased Regulatory Risk: Former FDA Commissioner Scott Gottlieb warns that Hims & Hers could face serious regulatory consequences for attempting to sell an unapproved GLP-1 drug, with the FDA referring the case to the DOJ, indicating aggressive enforcement actions may include injunctions or seizures.
- Importance of Drug Approval Process: Gottlieb emphasizes the necessity of the drug approval process, arguing that allowing companies to market untested formulations under pharmacy licenses undermines the safety and efficacy guarantees of medications.
- Loss of Industry Trust: Due to Hims & Hers' history of pushing regulatory boundaries, Gottlieb suggests that pharmaceutical companies are unlikely to partner with them in the future, as they are not perceived as compliant
See More
Novo Nordisk Sues Hims for Patent Infringement
- Patent Infringement Lawsuit: Novo Nordisk has filed a lawsuit against Hims & Hers, alleging infringement of its U.S. patent related to semaglutide and the unlawful marketing of compounded versions of its FDA-approved medications, Wegovy and Ozempic, aiming to protect patient safety and uphold regulatory standards.
- Safety Risk Warning: Novo Nordisk claims that the unapproved compounded products promoted by Hims may mislead patients and healthcare providers, increasing safety risks and potentially compromising patient health and treatment outcomes.
- Legal Relief Request: The company is seeking a permanent injunction to halt the sales of these compounded products and is requesting damages, demonstrating its firm stance on protecting intellectual property and market integrity.
- Market Reaction: Novo Nordisk's stock is trading at $50.16 on the New York Stock Exchange, up $2.49 or 5.21% from the previous trading day, reflecting a positive market response to its legal actions.
See More
Market Update: Microsoft Downgrade, Kroger's New CEO Announcement
- Microsoft Downgrade: Melius Research downgraded Microsoft from buy to hold, citing that CEO Satya Nadella has lost the AI narrative and that the stock appears overpriced based on new free cash flow estimates, which may undermine investor confidence.
- Eli Lilly Acquires Orna: Eli Lilly announced the acquisition of biotech firm Orna Therapeutics for up to $2.4 billion, leading to a premarket surge in Eli Lilly and rival Novo Nordisk shares, indicating a positive market response towards biotech investments.
- Kroger's New CEO: Kroger's stock advanced nearly 7% in premarket trading after reports indicated that former Walmart executive Greg Foran will be appointed as the new CEO, having previously led Walmart's U.S. division for six years, suggesting a strategic shift for Kroger.
- Robinhood Upgrade: Wolfe Research upgraded Robinhood from hold to buy, despite the stock's recent decline amid a major cryptocurrency sell-off, as analysts believe its future potential remains strong, which could attract renewed investor interest.
See More
Novo Nordisk Expects Earnings Decline in 2026
- Earnings Guidance Decline: Novo Nordisk's 2025 earnings report revealed a grim outlook for 2026, with sales and earnings expected to decline between 5% and 13%, primarily due to lower GLP-1 drug prices in the U.S., indicating significant market pressures and uncertainty regarding future profitability.
- Surge in GLP-1 Demand: Despite these challenges, the company's new GLP-1 pill attracted 170,000 patients within just four weeks of launch, far exceeding management's expectations, highlighting the potential growth opportunities in the weight-loss drug market.
- Increased Market Acceptance: The preference for oral medications over injections among consumers suggests that Novo Nordisk's GLP-1 pill could tap into a larger market, and the pricing agreement with the U.S. government further boosts demand, creating a favorable environment for sales growth.
- Optimistic Long-Term Outlook: Although Novo Nordisk's stock has lost two-thirds of its value since its peak in 2024, the early success of the pill indicates that future volume could offset the pricing pressures expected in 2026, with the CEO's comments reflecting a positive internal outlook for the company's future.
See More
Novo Nordisk Shares Surge After Competitor Withdraws Drug
- Stock Surge: Novo Nordisk shares jumped 8% on Monday following Hims & Hers' announcement to withdraw its copycat weight-loss pill, indicating increased market confidence in Novo Nordisk's products.
- Legal Threats: Novo Nordisk and the FDA had threatened legal action against Hims & Hers, prompting the withdrawal, which not only protects Novo Nordisk's market share but may also reshape competitive dynamics in the industry.
- Market Reaction: Hims & Hers stated on social media that after constructive conversations with industry stakeholders, they decided to stop offering the treatment, a move that could further solidify Novo Nordisk's leadership in the weight-loss drug market.
- Commitment to Safe Care: Hims & Hers emphasized its commitment to providing safe, affordable, and personalized care, and while the withdrawal may impact its trust among consumers, it reflects a strategic pivot in response to regulatory pressures.
See More
Eli Lilly Stock Bounces Back 2.4% After FDA Action Against Hims & Hers
- Stock Recovery: Eli Lilly (LLY) shares rebounded 2.4% by 9:50 a.m. ET on Monday, reflecting a recovery in market confidence after last week's decline due to Hims & Hers' announcement of an Ozempic lookalike, indicating resilience in its core product offerings.
- FDA Regulatory Action: The FDA's plans to crack down on Hims & Hers, potentially limiting access to ingredients for manufacturing Ozempic copies, triggered a positive market response over the weekend, further boosting Eli Lilly's stock price.
- Reduced Competitive Threat: Hims & Hers' decision to halt the sale of its Ozempic copycat alleviates competitive pressure on Eli Lilly, particularly regarding its pricing strategy for Zepbound and Mounjaro, thereby reinforcing Lilly's market position.
- Legal Action Impact: Novo Nordisk's lawsuit against Hims & Hers, seeking to prevent the sale of copycat drugs, not only protects Novo's market share but also indirectly benefits Eli Lilly by enhancing the competitive edge of its higher-priced products in the market.
See More
Hims & Hers Faces Serious Regulatory Consequences
- Increased Regulatory Risk: Former FDA Commissioner Scott Gottlieb warns that Hims & Hers could face serious regulatory consequences for attempting to sell an unapproved GLP-1 drug, with the FDA referring the case to the DOJ, indicating aggressive enforcement actions may include injunctions or seizures.
- Importance of Drug Approval Process: Gottlieb emphasizes the necessity of the drug approval process, arguing that allowing companies to market untested formulations under pharmacy licenses undermines the safety and efficacy guarantees of medications.
- Loss of Industry Trust: Due to Hims & Hers' history of pushing regulatory boundaries, Gottlieb suggests that pharmaceutical companies are unlikely to partner with them in the future, as they are not perceived as compliant
See More
Novo Nordisk Sues Hims for Patent Infringement
- Patent Infringement Lawsuit: Novo Nordisk has filed a lawsuit against Hims & Hers, alleging infringement of its U.S. patent related to semaglutide and the unlawful marketing of compounded versions of its FDA-approved medications, Wegovy and Ozempic, aiming to protect patient safety and uphold regulatory standards.
- Safety Risk Warning: Novo Nordisk claims that the unapproved compounded products promoted by Hims may mislead patients and healthcare providers, increasing safety risks and potentially compromising patient health and treatment outcomes.
- Legal Relief Request: The company is seeking a permanent injunction to halt the sales of these compounded products and is requesting damages, demonstrating its firm stance on protecting intellectual property and market integrity.
- Market Reaction: Novo Nordisk's stock is trading at $50.16 on the New York Stock Exchange, up $2.49 or 5.21% from the previous trading day, reflecting a positive market response to its legal actions.
See More
Market Update: Microsoft Downgrade, Kroger's New CEO Announcement
- Microsoft Downgrade: Melius Research downgraded Microsoft from buy to hold, citing that CEO Satya Nadella has lost the AI narrative and that the stock appears overpriced based on new free cash flow estimates, which may undermine investor confidence.
- Eli Lilly Acquires Orna: Eli Lilly announced the acquisition of biotech firm Orna Therapeutics for up to $2.4 billion, leading to a premarket surge in Eli Lilly and rival Novo Nordisk shares, indicating a positive market response towards biotech investments.
- Kroger's New CEO: Kroger's stock advanced nearly 7% in premarket trading after reports indicated that former Walmart executive Greg Foran will be appointed as the new CEO, having previously led Walmart's U.S. division for six years, suggesting a strategic shift for Kroger.
- Robinhood Upgrade: Wolfe Research upgraded Robinhood from hold to buy, despite the stock's recent decline amid a major cryptocurrency sell-off, as analysts believe its future potential remains strong, which could attract renewed investor interest.
See More
